Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IMRN vs EQ: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EQ Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

EQ Overall Winner 6-Pillar Tally: IMRN 2 – 3 EQ (1 Tie) Matrix Metrics: IMRN 5 – 5 EQ

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Immuron Limited (IMRN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). IMRN carries a Unified Composite Score of 53.6/100 (HOLD) at $0.85 (N/M Forward P/E, -46.2% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While IMRN currently prints a higher short-term Unified Composite Score (53.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -46.2% operating margin) and revenue trajectory (-52.3% vs. +7.2% YoY).
  • Technical & Structure Timing Caution: IMRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMRN vs EQ
IMRN NASDAQ
Immuron Limited American Depositary Shares
Pharmaceutical Preparations
$0.85
-1.89% 1D
Market Cap $6.9M
TTM Revenue $7.7M
Forward P/E N/M
Beta / 30D Vol 0.45β · 45% Vol
Unified Composite Score
53.6 / 100 HOLD
Tech 58.0 Fund 59.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -12.5%), weak momentum, RSI 38
RSI-14: 38.0 · SMA20: $0.89 · SMA50: $1.03
EQ NASDAQ Head-to-Head Winner
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
TTM Revenue $4.4M
Forward P/E 1.5x
Beta / 30D Vol 1.53β · 93% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.8%), weak momentum, RSI 36
RSI-14: 36.0 · SMA20: $1.33 · SMA50: $1.49

6-Pillar Scorecard Institutional Category Breakdown (IMRN 2 – 3 EQ)

Columns: Metric · IMRN · EQ
1. Valuation Multiples EQ
Forward P/E N/M 1.5x
Trailing P/E N/M 1.5x
PEG Ratio N/M N/M
EV / Revenue 0.9x 7.7x
2. Growth & Scale IMRN
Revenue Growth (YoY) +7.2% -52.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $7.7M $4.4M
Market Cap $6.9M $90.6M
3. Profitability & Quality EQ
Gross Margin 64.5% 100.0%
Operating Margin -46.2% 0.0%
Net Profit Margin -47.7% 0.0%
Return on Equity (ROE) -38.3% -59.0%
4. Balance Sheet & Cash Flow IMRN
Cash Generation (TTM) -$3.5M EBITDA -$20M
Cash Flow Margin -45.7% EBITDA Mgn N/A
Net Cash / Leverage $0.98 Book/Sh · -38.3% ROE $57M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EQ
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 261.3% (100th %ile)
Put/Call OI Skew Thin ADR Chain N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMRN (5) vs EQ (5)
Institutional Metric IMRN EQ Criterion Row Edge
Market Capitalization
Scale
$6.9M $90.6M Larger Scale EQ
Trailing P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Forward P/E Ratio
Valuation
N/M 1.5x Lower Multiple EQ
Revenue Growth (YoY)
Growth
+7.2% -52.3% Higher Growth IMRN
Operating Margin (TTM)
Profitability
-46.2% 0.0% Higher Margin EQ
Net Profit Margin
Profitability
-47.7% 0.0% Higher Margin EQ
Return on Equity (ROE)
Capital Efficiency
-38.3% -59.0% Higher ROE IMRN
52-Week Range Position
Momentum
13% ($1–$2) 11% ($1–$4) Stronger Trend IMRN
Beta / 30D Volatility
Risk Regime
0.45β · 45% Vol 1.53β · 93% Vol Lower Realized Risk IMRN
Unified Institutional Score
Composite Signal
53.6 / 100 (HOLD) 48.0 / 100 (HOLD) Higher Composite IMRN
Trailing 12M Revenue (USD)
Operating Scale
$7.7M $4.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.5% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 7.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$3.5M EBITDA ($0.98 Book/Sh · -38.3% ROE) -$20M ($57M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IMRN +8.76 pp
IMRN: -12.37% · EQ: -21.13%
3M Horizon IMRN +27.41 pp
IMRN: -24.11% · EQ: -51.52%
6M Horizon IMRN +36.05 pp
IMRN: -13.27% · EQ: -49.32%
1Y Horizon EQ +57.51 pp
IMRN: -45.51% · EQ: +12.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMRN vs EQ. Trailing 12-month operating profitability (IMRN -46.2% vs EQ 0.0%) and valuation multiples (IMRN N/M vs EQ 1.5x Forward P/E) are benchmarked directly in Pillar 4 below.

IMRN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$7.7M
Gross Margin64.5%
Op. Margin-46.2%
ROE / Fwd P/E-38.3% · N/M
EQ ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.4M
Gross Margin100.0%
Op. Margin0.0%
ROE / Fwd P/E-59.0% · 1.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMRN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMRN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
EQ UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 261.3%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EQ Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMRN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.9M market capitalization and -46.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
EQ Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $90.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMRN vs EQ Key Questions & Quantitative Answers

As of Nov 19, 2026, Equillium, Inc. (EQ) is the stronger overall head-to-head candidate over Immuron Limited (IMRN) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). IMRN carries a Unified Composite Score of 53.6/100 (HOLD) at $0.85 (N/M Forward P/E, -46.2% operating margin), whereas EQ carries 48.0/100 (HOLD) at $1.12 (1.5x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While IMRN currently prints a higher short-term Unified Composite Score (53.6/100 HOLD vs. EQ 48.0/100 HOLD), EQ captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -46.2% operating margin) and revenue trajectory (-52.3% vs. +7.2% YoY). Technical & Structure Timing Caution: IMRN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.0); meanwhile EQ is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMRN leads the Growth & Scale pillar: IMRN posts +7.2% YoY revenue growth and +0.0% YoY earnings growth on $7.7M TTM revenue (64.5% gross margin, -46.2% operating margin), compared with EQ at -52.3% YoY revenue growth and +0.0% YoY earnings growth on $4.4M TTM revenue (100.0% gross margin, 0.0% operating margin). On trailing 12-month operating scale, IMRN generates $7.7M in USD-normalized revenue versus $4.4M for EQ. In operating R&D and SG&A reinvestment, IMRN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for EQ.

EQ screens cheaper on headline valuation multiples. IMRN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.9x EV/Revenue (-45.7% EBITDA margin), whereas EQ trades at 1.5x Forward P/E, 1.5x Trailing P/E, N/M PEG, and 7.7x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMRN (-38.3% ROE) versus EQ (-59.0% ROE) capital efficiency.

In options market volatility and institutional positioning, IMRN carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 45% Vol realized risk). By comparison, EQ carries 261.3% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.53β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.